A Study of 99mTc-3PRGD2 Injection in Lung Cancer Patient
Status:
Recruiting
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
The study drug Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide
Injection（99mTc-3PRGD2） of this study is a novel radioactive diagnostic preparation for
clinical use as a nuclear medicine molecular probe for tumor SPECT/CT imaging.
After 99mTc-3PRGD2 is injected into the body, it is specifically taken up by integrin
receptor-positive tumor tissue, and the image of tumor tissue can be obtained by SPECT/CT,
This can be used for molecular imaging diagnosis and individualized treatment of common
tumors.
The primary objective of this study was to evaluate the efficacy of 99mTc-3PRGD2 for the
diagnosis of lymph node metastasis in lung tumors. The minor objective was to evaluate the
efficacy of 99mTc-3PRGD2 in the differential diagnosis of benign and malignant lung tumors
and the safety of 99mTc-3PRGD2 in vivo of humans.